Exclusive study “Use of NGS to replace animal tests for the viral safety of biologics”
Industry stakeholders need rapid and robust testing strategies to ensure their products and patients’ safety. Doing so they are seeking long-term strategies around sustainability and animal welfare. Choosing NGS-based biosafety services will help them comply with the principles of the 3R: refine, replace, and reduce animal testing.
In those dedicated events, our experts will present the results of the first biosafety study.
This 30-month long unprecedented study was jointly conducted by PathoQuest and Charles River and provides extended arguments for the adoption of NGS-based testing as a prime substitutive method to animal testing.
On-Invite Only Webinar
2021 PDA Europe Virus Forum
4th Annual NGS Seminar
Pascale Beurdeley, Ph.D.
PathoQuest’s Chief Scientific Officer
She has over 20 years of experience in genomics and next-generation sequencing toward biotechtechnology industries. Dr. Beurdeley oversees the technical development of the clinical and biologics activities of PathoQuest’s portfolio.
Marc Eloit, DVM, Ph.D.
Founder of PathoQuest
He is Professor of Virology and the former head of the Virology Unit at the Veterinary School of Maisons-Alfort. He joined Institut Pasteur in 2008 to develop a program of Pathogen Discovery based on Next Generation Sequencing (NGS).
Horst Ruppach, Ph.D.
Scientific & Portfolio Director, Charles River
He has 25 years of experience in the field of virology. His expertise is in virus safety testing and virus/prion clearances studies requested for all biopharmaceuticals and medical devices using animal- or human-derived materials.
If you wish to attend or have more information about this exclusive webinar please send us a request through this form.